Scale Biosciences, Inc.

Scale Biosciences, Inc. is a US-based company specializing in innovative solutions for single-cell research, focusing on advanced technologies such as the QuantumScale platform for genomic applications. Founded in 2020 and headquartered in San Diego, US, Scale Biosciences, Inc. develops cutting-edge single-cell research technologies.

The company has successfully raised USD 32. 00 mn in funding through its latest round, attracting investors like ARCH Venture Partners and Tao Capital Partners. Scale Biosciences has completed a total of 2 deals to date, positioning itself as a key player in the biotechnology sector. Scale Biosciences specializes in innovative solutions for single-cell research, predominantly through its QuantumScale platform, which includes Single Cell RNA and Methylation kits.

These products facilitate efficient preparation of single-cell libraries, allowing researchers to conduct experiments across a wide range of conditions, from tens to thousands of samples or timepoints, and can handle hundreds to millions of cells. The technologies aim to streamline sample collection and multiplexing, preserving precious biological samples while significantly reducing the time and effort required for experimental workflows. Scale Biosciences targets a diverse client base within the biotechnology and academic research sectors, particularly those focused on genomics, cancer biology, and complex disease research. The company distributes its products primarily in North America, Europe, and Asia, addressing the needs of various global research institutions.

Scale Biosciences generates revenue through the sale of its proprietary single-cell library preparation kits, primarily marketed to research institutions and biotechnology companies involved in genomic studies. Transactions typically occur on a B2B basis, with clients purchasing products directly from the company or through authorized distributors. The pricing structure reflects the advanced nature of these technologies, with flagship offerings such as the QuantumScale Single Cell RNA kits being integral to the company’s portfolio. As the market demand for scalable and efficient single-cell analysis tools increases, Scale Biosciences’ products are positioned to meet these needs, driving consistent revenue from both existing clients and new users seeking cost-effective solutions in genomic research.

Scale Biosciences plans to utilize the USD 32. 00 mn raised from the latest funding round to develop new products and expand into new geographical markets. The company aims to enhance its QuantumScale platform, potentially launching additional kits by 2024. Furthermore, it is targeting expansion into Asia-Pacific markets by the end of 2025, thereby broadening its reach in the global research community.

The recent investment will support these initiatives and facilitate the development of innovative technologies to meet the increasing demands within the life sciences sector.